BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS-期刊论坛，投稿经验-MedSci.cn

[GetPortalCommentsPageByObjectIdResponse(id=2198240, encodeId=46732198240d3, content=审稿速度:1.0 | 投稿命中率:5.0 偏重的研究方向：胃癌;普通外科 经验分享：3.26号投稿，2周后under review，1周后4.8日要求一些小的图片细节修改。修改了2天。4.11再次submit，8小时后reject。有点摸不清是什么意思。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c18b9149683, createdName=ms8000000859382731, createdTime=Sat Apr 13 01:12:03 CST 2024, time=2024-04-13, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=2188858, encodeId=577d21888581a, content=偏重的研究方向：鼻息肉;适应性免疫;人慢性鼻窦炎 经验分享：记录一下：投的short communication，编号：24-1285。2024.02.15 Submitted to journal，2024.02.21 Under Review。跪求诸神保佑文章可以accept！, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=17, replyNumber=6, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=90a81637022, createdName=1dd97911m23(暂无匿称), createdTime=Fri Feb 23 11:34:34 CST 2024, time=2024-02-23, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=2197697, encodeId=4bff219e6979c, content=正在投稿中, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=1, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8c615403200, createdName=ms8000000618836174, createdTime=Wed Apr 10 09:28:44 CST 2024, time=2024-04-10, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=2194249, encodeId=417e2194249d3, content=效率还可以，稳妥Accept, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=12, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/202403/72312163c68e4099952942b04fa6f369-k56lKDLhTfUF.jpg, createdBy=39cc9222865, createdName=零零一, createdTime=Wed Mar 20 11:31:37 CST 2024, time=2024-03-20, status=1, ipAttribution=广西), GetPortalCommentsPageByObjectIdResponse(id=2188536, encodeId=531a218853681, content=偏重的研究方向：中药生发 经验分享：2024.2.18晚上22.54投稿，2.19号凌晨12.59处于Submitted to Journal状态，到今天已经三天了还是Submitted to Journal状态，编号： BBRC-24-1364，期待能有个好结果吧，毕业用，不知道能不能来得及，唉, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=19, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a2ab8713797, createdName=ms8000000394868318, createdTime=Wed Feb 21 17:21:12 CST 2024, time=2024-02-21, status=1, ipAttribution=四川省), GetPortalCommentsPageByObjectIdResponse(id=804128, encodeId=c2f9804128b3, content=审稿速度:1.0 | 投稿命中率:100.0 偏重的研究方向：神经生物学;细胞生物学;分子生物学 经验分享：赶着毕业拿学位，投稿BBRC，非常给力！7月19日晚上提交，立刻分配了稿件号并with editor，7月21日下午稿件退回要求补充上传WB的original images，当天补充完提交，提交后1小时就under review，今天7月23日中午接收，从初次提交到接收用时4天，十分效率！, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=335, replyNumber=56, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ba294682334, createdName=17142086d7m, createdTime=Thu Jul 23 15:29:56 CST 2020, time=2020-07-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2175767, encodeId=b94121e5767ad, content=审稿速度:1.0 | 投稿命中率:50.0 偏重的研究方向：动物实验;心血管;基础 经验分享：投的short communications，时间线参考： 2023.12.03 Submitted to Journal 2023.12.14 Pre-review changes required 2023.12.15 Under Review 2023.12.18 Accept 一共给BBRC投过3次稿，拒稿转投1次，接收2次。这次从Under Review到接收只花了3天，个人感觉是BBRC更注重课题的创新，逻辑思路的清晰和语言的凝练。不需要有过多的数据，但是需要有新意。按照我的经验，越快审稿说明新意越足，中的概率越大。祝大家也顺利。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=68, replyNumber=10, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTLzaUvYjJ5RKldIwAUubutpwZa2IpTuAibHjwEMk8vGIqwxTR3GEGYzO1jKlxVb3XHe6p8HNUCFt8g/132, createdBy=597d5310028, createdName=寻觅瓦尔登, createdTime=Tue Dec 19 10:51:42 CST 2023, time=2023-12-19, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=2194888, encodeId=a44f2194888de, content=请问BBRC文章查重文献和图例也查吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=7, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=13e69228095, createdName=ms9000000037149974, createdTime=Sat Mar 23 18:02:22 CST 2024, time=2024-03-23, status=1, ipAttribution=山东省), GetPortalCommentsPageByObjectIdResponse(id=2194841, encodeId=314421948414c, content=稿费多少, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=9, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9d3f9227750, createdName=ms6000001807387082, createdTime=Sat Mar 23 12:08:06 CST 2024, time=2024-03-23, status=1, ipAttribution=辽宁省), GetPortalCommentsPageByObjectIdResponse(id=2174194, encodeId=63c121e4194a6, content=11天了还是Submitted to journal,请问什么时候能进入下一节点啊, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=50, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=1b708136833, createdName=ms1000000877479508, createdTime=Mon Dec 11 09:14:15 CST 2023, time=2023-12-11, status=1, ipAttribution=海南省)]

2024-04-13 ms8000000859382731 来自北京

审稿速度:1.0 | 投稿命中率:5.0
偏重的研究方向：胃癌;普通外科
经验分享：3.26号投稿，2周后under review，1周后4.8日要求一些小的图片细节修改。修改了2天。4.11再次submit，8小时后reject。有点摸不清是什么意思。

0 0

[GetPortalCommentsPageByObjectIdResponse(id=2198240, encodeId=46732198240d3, content=审稿速度:1.0 | 投稿命中率:5.0 偏重的研究方向：胃癌;普通外科 经验分享：3.26号投稿，2周后under review，1周后4.8日要求一些小的图片细节修改。修改了2天。4.11再次submit，8小时后reject。有点摸不清是什么意思。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c18b9149683, createdName=ms8000000859382731, createdTime=Sat Apr 13 01:12:03 CST 2024, time=2024-04-13, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=2188858, encodeId=577d21888581a, content=偏重的研究方向：鼻息肉;适应性免疫;人慢性鼻窦炎 经验分享：记录一下：投的short communication，编号：24-1285。2024.02.15 Submitted to journal，2024.02.21 Under Review。跪求诸神保佑文章可以accept！, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=17, replyNumber=6, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=90a81637022, createdName=1dd97911m23(暂无匿称), createdTime=Fri Feb 23 11:34:34 CST 2024, time=2024-02-23, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=2197697, encodeId=4bff219e6979c, content=正在投稿中, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=1, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8c615403200, createdName=ms8000000618836174, createdTime=Wed Apr 10 09:28:44 CST 2024, time=2024-04-10, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=2194249, encodeId=417e2194249d3, content=效率还可以，稳妥Accept, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=12, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/202403/72312163c68e4099952942b04fa6f369-k56lKDLhTfUF.jpg, createdBy=39cc9222865, createdName=零零一, createdTime=Wed Mar 20 11:31:37 CST 2024, time=2024-03-20, status=1, ipAttribution=广西), GetPortalCommentsPageByObjectIdResponse(id=2188536, encodeId=531a218853681, content=偏重的研究方向：中药生发 经验分享：2024.2.18晚上22.54投稿，2.19号凌晨12.59处于Submitted to Journal状态，到今天已经三天了还是Submitted to Journal状态，编号： BBRC-24-1364，期待能有个好结果吧，毕业用，不知道能不能来得及，唉, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=19, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a2ab8713797, createdName=ms8000000394868318, createdTime=Wed Feb 21 17:21:12 CST 2024, time=2024-02-21, status=1, ipAttribution=四川省), GetPortalCommentsPageByObjectIdResponse(id=804128, encodeId=c2f9804128b3, content=审稿速度:1.0 | 投稿命中率:100.0 偏重的研究方向：神经生物学;细胞生物学;分子生物学 经验分享：赶着毕业拿学位，投稿BBRC，非常给力！7月19日晚上提交，立刻分配了稿件号并with editor，7月21日下午稿件退回要求补充上传WB的original images，当天补充完提交，提交后1小时就under review，今天7月23日中午接收，从初次提交到接收用时4天，十分效率！, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=335, replyNumber=56, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ba294682334, createdName=17142086d7m, createdTime=Thu Jul 23 15:29:56 CST 2020, time=2020-07-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2175767, encodeId=b94121e5767ad, content=审稿速度:1.0 | 投稿命中率:50.0 偏重的研究方向：动物实验;心血管;基础 经验分享：投的short communications，时间线参考： 2023.12.03 Submitted to Journal 2023.12.14 Pre-review changes required 2023.12.15 Under Review 2023.12.18 Accept 一共给BBRC投过3次稿，拒稿转投1次，接收2次。这次从Under Review到接收只花了3天，个人感觉是BBRC更注重课题的创新，逻辑思路的清晰和语言的凝练。不需要有过多的数据，但是需要有新意。按照我的经验，越快审稿说明新意越足，中的概率越大。祝大家也顺利。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=68, replyNumber=10, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTLzaUvYjJ5RKldIwAUubutpwZa2IpTuAibHjwEMk8vGIqwxTR3GEGYzO1jKlxVb3XHe6p8HNUCFt8g/132, createdBy=597d5310028, createdName=寻觅瓦尔登, createdTime=Tue Dec 19 10:51:42 CST 2023, time=2023-12-19, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=2194888, encodeId=a44f2194888de, content=请问BBRC文章查重文献和图例也查吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=7, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=13e69228095, createdName=ms9000000037149974, createdTime=Sat Mar 23 18:02:22 CST 2024, time=2024-03-23, status=1, ipAttribution=山东省), GetPortalCommentsPageByObjectIdResponse(id=2194841, encodeId=314421948414c, content=稿费多少, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=9, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9d3f9227750, createdName=ms6000001807387082, createdTime=Sat Mar 23 12:08:06 CST 2024, time=2024-03-23, status=1, ipAttribution=辽宁省), GetPortalCommentsPageByObjectIdResponse(id=2174194, encodeId=63c121e4194a6, content=11天了还是Submitted to journal,请问什么时候能进入下一节点啊, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=50, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=1b708136833, createdName=ms1000000877479508, createdTime=Mon Dec 11 09:14:15 CST 2023, time=2023-12-11, status=1, ipAttribution=海南省)]

2024-02-23 1dd97911m23(暂无匿称) 来自北京

偏重的研究方向：鼻息肉;适应性免疫;人慢性鼻窦炎
经验分享：记录一下：投的short communication，编号：24-1285。2024.02.15 Submitted to journal，2024.02.21 Under Review。跪求诸神保佑文章可以accept！

17 6

展开6条回复

[GetPortalCommentsPageByObjectIdResponse(id=2198240, encodeId=46732198240d3, content=审稿速度:1.0 | 投稿命中率:5.0 偏重的研究方向：胃癌;普通外科 经验分享：3.26号投稿，2周后under review，1周后4.8日要求一些小的图片细节修改。修改了2天。4.11再次submit，8小时后reject。有点摸不清是什么意思。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c18b9149683, createdName=ms8000000859382731, createdTime=Sat Apr 13 01:12:03 CST 2024, time=2024-04-13, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=2188858, encodeId=577d21888581a, content=偏重的研究方向：鼻息肉;适应性免疫;人慢性鼻窦炎 经验分享：记录一下：投的short communication，编号：24-1285。2024.02.15 Submitted to journal，2024.02.21 Under Review。跪求诸神保佑文章可以accept！, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=17, replyNumber=6, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=90a81637022, createdName=1dd97911m23(暂无匿称), createdTime=Fri Feb 23 11:34:34 CST 2024, time=2024-02-23, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=2197697, encodeId=4bff219e6979c, content=正在投稿中, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=1, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8c615403200, createdName=ms8000000618836174, createdTime=Wed Apr 10 09:28:44 CST 2024, time=2024-04-10, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=2194249, encodeId=417e2194249d3, content=效率还可以，稳妥Accept, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=12, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/202403/72312163c68e4099952942b04fa6f369-k56lKDLhTfUF.jpg, createdBy=39cc9222865, createdName=零零一, createdTime=Wed Mar 20 11:31:37 CST 2024, time=2024-03-20, status=1, ipAttribution=广西), GetPortalCommentsPageByObjectIdResponse(id=2188536, encodeId=531a218853681, content=偏重的研究方向：中药生发 经验分享：2024.2.18晚上22.54投稿，2.19号凌晨12.59处于Submitted to Journal状态，到今天已经三天了还是Submitted to Journal状态，编号： BBRC-24-1364，期待能有个好结果吧，毕业用，不知道能不能来得及，唉, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=19, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a2ab8713797, createdName=ms8000000394868318, createdTime=Wed Feb 21 17:21:12 CST 2024, time=2024-02-21, status=1, ipAttribution=四川省), GetPortalCommentsPageByObjectIdResponse(id=804128, encodeId=c2f9804128b3, content=审稿速度:1.0 | 投稿命中率:100.0 偏重的研究方向：神经生物学;细胞生物学;分子生物学 经验分享：赶着毕业拿学位，投稿BBRC，非常给力！7月19日晚上提交，立刻分配了稿件号并with editor，7月21日下午稿件退回要求补充上传WB的original images，当天补充完提交，提交后1小时就under review，今天7月23日中午接收，从初次提交到接收用时4天，十分效率！, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=335, replyNumber=56, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ba294682334, createdName=17142086d7m, createdTime=Thu Jul 23 15:29:56 CST 2020, time=2020-07-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2175767, encodeId=b94121e5767ad, content=审稿速度:1.0 | 投稿命中率:50.0 偏重的研究方向：动物实验;心血管;基础 经验分享：投的short communications，时间线参考： 2023.12.03 Submitted to Journal 2023.12.14 Pre-review changes required 2023.12.15 Under Review 2023.12.18 Accept 一共给BBRC投过3次稿，拒稿转投1次，接收2次。这次从Under Review到接收只花了3天，个人感觉是BBRC更注重课题的创新，逻辑思路的清晰和语言的凝练。不需要有过多的数据，但是需要有新意。按照我的经验，越快审稿说明新意越足，中的概率越大。祝大家也顺利。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=68, replyNumber=10, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTLzaUvYjJ5RKldIwAUubutpwZa2IpTuAibHjwEMk8vGIqwxTR3GEGYzO1jKlxVb3XHe6p8HNUCFt8g/132, createdBy=597d5310028, createdName=寻觅瓦尔登, createdTime=Tue Dec 19 10:51:42 CST 2023, time=2023-12-19, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=2194888, encodeId=a44f2194888de, content=请问BBRC文章查重文献和图例也查吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=7, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=13e69228095, createdName=ms9000000037149974, createdTime=Sat Mar 23 18:02:22 CST 2024, time=2024-03-23, status=1, ipAttribution=山东省), GetPortalCommentsPageByObjectIdResponse(id=2194841, encodeId=314421948414c, content=稿费多少, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=9, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9d3f9227750, createdName=ms6000001807387082, createdTime=Sat Mar 23 12:08:06 CST 2024, time=2024-03-23, status=1, ipAttribution=辽宁省), GetPortalCommentsPageByObjectIdResponse(id=2174194, encodeId=63c121e4194a6, content=11天了还是Submitted to journal,请问什么时候能进入下一节点啊, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=50, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=1b708136833, createdName=ms1000000877479508, createdTime=Mon Dec 11 09:14:15 CST 2023, time=2023-12-11, status=1, ipAttribution=海南省)]

2024-04-10 ms8000000618836174 来自广东省

正在投稿中

1 1

展开1条回复

[GetPortalCommentsPageByObjectIdResponse(id=2198240, encodeId=46732198240d3, content=审稿速度:1.0 | 投稿命中率:5.0 偏重的研究方向：胃癌;普通外科 经验分享：3.26号投稿，2周后under review，1周后4.8日要求一些小的图片细节修改。修改了2天。4.11再次submit，8小时后reject。有点摸不清是什么意思。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c18b9149683, createdName=ms8000000859382731, createdTime=Sat Apr 13 01:12:03 CST 2024, time=2024-04-13, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=2188858, encodeId=577d21888581a, content=偏重的研究方向：鼻息肉;适应性免疫;人慢性鼻窦炎 经验分享：记录一下：投的short communication，编号：24-1285。2024.02.15 Submitted to journal，2024.02.21 Under Review。跪求诸神保佑文章可以accept！, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=17, replyNumber=6, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=90a81637022, createdName=1dd97911m23(暂无匿称), createdTime=Fri Feb 23 11:34:34 CST 2024, time=2024-02-23, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=2197697, encodeId=4bff219e6979c, content=正在投稿中, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=1, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8c615403200, createdName=ms8000000618836174, createdTime=Wed Apr 10 09:28:44 CST 2024, time=2024-04-10, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=2194249, encodeId=417e2194249d3, content=效率还可以，稳妥Accept, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=12, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/202403/72312163c68e4099952942b04fa6f369-k56lKDLhTfUF.jpg, createdBy=39cc9222865, createdName=零零一, createdTime=Wed Mar 20 11:31:37 CST 2024, time=2024-03-20, status=1, ipAttribution=广西), GetPortalCommentsPageByObjectIdResponse(id=2188536, encodeId=531a218853681, content=偏重的研究方向：中药生发 经验分享：2024.2.18晚上22.54投稿，2.19号凌晨12.59处于Submitted to Journal状态，到今天已经三天了还是Submitted to Journal状态，编号： BBRC-24-1364，期待能有个好结果吧，毕业用，不知道能不能来得及，唉, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=19, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a2ab8713797, createdName=ms8000000394868318, createdTime=Wed Feb 21 17:21:12 CST 2024, time=2024-02-21, status=1, ipAttribution=四川省), GetPortalCommentsPageByObjectIdResponse(id=804128, encodeId=c2f9804128b3, content=审稿速度:1.0 | 投稿命中率:100.0 偏重的研究方向：神经生物学;细胞生物学;分子生物学 经验分享：赶着毕业拿学位，投稿BBRC，非常给力！7月19日晚上提交，立刻分配了稿件号并with editor，7月21日下午稿件退回要求补充上传WB的original images，当天补充完提交，提交后1小时就under review，今天7月23日中午接收，从初次提交到接收用时4天，十分效率！, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=335, replyNumber=56, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ba294682334, createdName=17142086d7m, createdTime=Thu Jul 23 15:29:56 CST 2020, time=2020-07-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2175767, encodeId=b94121e5767ad, content=审稿速度:1.0 | 投稿命中率:50.0 偏重的研究方向：动物实验;心血管;基础 经验分享：投的short communications，时间线参考： 2023.12.03 Submitted to Journal 2023.12.14 Pre-review changes required 2023.12.15 Under Review 2023.12.18 Accept 一共给BBRC投过3次稿，拒稿转投1次，接收2次。这次从Under Review到接收只花了3天，个人感觉是BBRC更注重课题的创新，逻辑思路的清晰和语言的凝练。不需要有过多的数据，但是需要有新意。按照我的经验，越快审稿说明新意越足，中的概率越大。祝大家也顺利。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=68, replyNumber=10, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTLzaUvYjJ5RKldIwAUubutpwZa2IpTuAibHjwEMk8vGIqwxTR3GEGYzO1jKlxVb3XHe6p8HNUCFt8g/132, createdBy=597d5310028, createdName=寻觅瓦尔登, createdTime=Tue Dec 19 10:51:42 CST 2023, time=2023-12-19, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=2194888, encodeId=a44f2194888de, content=请问BBRC文章查重文献和图例也查吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=7, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=13e69228095, createdName=ms9000000037149974, createdTime=Sat Mar 23 18:02:22 CST 2024, time=2024-03-23, status=1, ipAttribution=山东省), GetPortalCommentsPageByObjectIdResponse(id=2194841, encodeId=314421948414c, content=稿费多少, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=9, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9d3f9227750, createdName=ms6000001807387082, createdTime=Sat Mar 23 12:08:06 CST 2024, time=2024-03-23, status=1, ipAttribution=辽宁省), GetPortalCommentsPageByObjectIdResponse(id=2174194, encodeId=63c121e4194a6, content=11天了还是Submitted to journal,请问什么时候能进入下一节点啊, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=50, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=1b708136833, createdName=ms1000000877479508, createdTime=Mon Dec 11 09:14:15 CST 2023, time=2023-12-11, status=1, ipAttribution=海南省)]

2024-03-20 零零一来自广西

效率还可以，稳妥Accept

12 1

展开1条回复

[GetPortalCommentsPageByObjectIdResponse(id=2198240, encodeId=46732198240d3, content=审稿速度:1.0 | 投稿命中率:5.0 偏重的研究方向：胃癌;普通外科 经验分享：3.26号投稿，2周后under review，1周后4.8日要求一些小的图片细节修改。修改了2天。4.11再次submit，8小时后reject。有点摸不清是什么意思。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c18b9149683, createdName=ms8000000859382731, createdTime=Sat Apr 13 01:12:03 CST 2024, time=2024-04-13, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=2188858, encodeId=577d21888581a, content=偏重的研究方向：鼻息肉;适应性免疫;人慢性鼻窦炎 经验分享：记录一下：投的short communication，编号：24-1285。2024.02.15 Submitted to journal，2024.02.21 Under Review。跪求诸神保佑文章可以accept！, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=17, replyNumber=6, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=90a81637022, createdName=1dd97911m23(暂无匿称), createdTime=Fri Feb 23 11:34:34 CST 2024, time=2024-02-23, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=2197697, encodeId=4bff219e6979c, content=正在投稿中, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=1, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8c615403200, createdName=ms8000000618836174, createdTime=Wed Apr 10 09:28:44 CST 2024, time=2024-04-10, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=2194249, encodeId=417e2194249d3, content=效率还可以，稳妥Accept, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=12, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/202403/72312163c68e4099952942b04fa6f369-k56lKDLhTfUF.jpg, createdBy=39cc9222865, createdName=零零一, createdTime=Wed Mar 20 11:31:37 CST 2024, time=2024-03-20, status=1, ipAttribution=广西), GetPortalCommentsPageByObjectIdResponse(id=2188536, encodeId=531a218853681, content=偏重的研究方向：中药生发 经验分享：2024.2.18晚上22.54投稿，2.19号凌晨12.59处于Submitted to Journal状态，到今天已经三天了还是Submitted to Journal状态，编号： BBRC-24-1364，期待能有个好结果吧，毕业用，不知道能不能来得及，唉, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=19, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a2ab8713797, createdName=ms8000000394868318, createdTime=Wed Feb 21 17:21:12 CST 2024, time=2024-02-21, status=1, ipAttribution=四川省), GetPortalCommentsPageByObjectIdResponse(id=804128, encodeId=c2f9804128b3, content=审稿速度:1.0 | 投稿命中率:100.0 偏重的研究方向：神经生物学;细胞生物学;分子生物学 经验分享：赶着毕业拿学位，投稿BBRC，非常给力！7月19日晚上提交，立刻分配了稿件号并with editor，7月21日下午稿件退回要求补充上传WB的original images，当天补充完提交，提交后1小时就under review，今天7月23日中午接收，从初次提交到接收用时4天，十分效率！, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=335, replyNumber=56, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ba294682334, createdName=17142086d7m, createdTime=Thu Jul 23 15:29:56 CST 2020, time=2020-07-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2175767, encodeId=b94121e5767ad, content=审稿速度:1.0 | 投稿命中率:50.0 偏重的研究方向：动物实验;心血管;基础 经验分享：投的short communications，时间线参考： 2023.12.03 Submitted to Journal 2023.12.14 Pre-review changes required 2023.12.15 Under Review 2023.12.18 Accept 一共给BBRC投过3次稿，拒稿转投1次，接收2次。这次从Under Review到接收只花了3天，个人感觉是BBRC更注重课题的创新，逻辑思路的清晰和语言的凝练。不需要有过多的数据，但是需要有新意。按照我的经验，越快审稿说明新意越足，中的概率越大。祝大家也顺利。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=68, replyNumber=10, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTLzaUvYjJ5RKldIwAUubutpwZa2IpTuAibHjwEMk8vGIqwxTR3GEGYzO1jKlxVb3XHe6p8HNUCFt8g/132, createdBy=597d5310028, createdName=寻觅瓦尔登, createdTime=Tue Dec 19 10:51:42 CST 2023, time=2023-12-19, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=2194888, encodeId=a44f2194888de, content=请问BBRC文章查重文献和图例也查吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=7, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=13e69228095, createdName=ms9000000037149974, createdTime=Sat Mar 23 18:02:22 CST 2024, time=2024-03-23, status=1, ipAttribution=山东省), GetPortalCommentsPageByObjectIdResponse(id=2194841, encodeId=314421948414c, content=稿费多少, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=9, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9d3f9227750, createdName=ms6000001807387082, createdTime=Sat Mar 23 12:08:06 CST 2024, time=2024-03-23, status=1, ipAttribution=辽宁省), GetPortalCommentsPageByObjectIdResponse(id=2174194, encodeId=63c121e4194a6, content=11天了还是Submitted to journal,请问什么时候能进入下一节点啊, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=50, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=1b708136833, createdName=ms1000000877479508, createdTime=Mon Dec 11 09:14:15 CST 2023, time=2023-12-11, status=1, ipAttribution=海南省)]

2024-02-21 ms8000000394868318 来自四川省

偏重的研究方向：中药生发
经验分享：2024.2.18晚上22.54投稿，2.19号凌晨12.59处于Submitted to Journal状态，到今天已经三天了还是Submitted to Journal状态，编号： BBRC-24-1364，期待能有个好结果吧，毕业用，不知道能不能来得及，唉

19 5

展开5条回复

[GetPortalCommentsPageByObjectIdResponse(id=2198240, encodeId=46732198240d3, content=审稿速度:1.0 | 投稿命中率:5.0 偏重的研究方向：胃癌;普通外科 经验分享：3.26号投稿，2周后under review，1周后4.8日要求一些小的图片细节修改。修改了2天。4.11再次submit，8小时后reject。有点摸不清是什么意思。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c18b9149683, createdName=ms8000000859382731, createdTime=Sat Apr 13 01:12:03 CST 2024, time=2024-04-13, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=2188858, encodeId=577d21888581a, content=偏重的研究方向：鼻息肉;适应性免疫;人慢性鼻窦炎 经验分享：记录一下：投的short communication，编号：24-1285。2024.02.15 Submitted to journal，2024.02.21 Under Review。跪求诸神保佑文章可以accept！, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=17, replyNumber=6, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=90a81637022, createdName=1dd97911m23(暂无匿称), createdTime=Fri Feb 23 11:34:34 CST 2024, time=2024-02-23, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=2197697, encodeId=4bff219e6979c, content=正在投稿中, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=1, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8c615403200, createdName=ms8000000618836174, createdTime=Wed Apr 10 09:28:44 CST 2024, time=2024-04-10, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=2194249, encodeId=417e2194249d3, content=效率还可以，稳妥Accept, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=12, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/202403/72312163c68e4099952942b04fa6f369-k56lKDLhTfUF.jpg, createdBy=39cc9222865, createdName=零零一, createdTime=Wed Mar 20 11:31:37 CST 2024, time=2024-03-20, status=1, ipAttribution=广西), GetPortalCommentsPageByObjectIdResponse(id=2188536, encodeId=531a218853681, content=偏重的研究方向：中药生发 经验分享：2024.2.18晚上22.54投稿，2.19号凌晨12.59处于Submitted to Journal状态，到今天已经三天了还是Submitted to Journal状态，编号： BBRC-24-1364，期待能有个好结果吧，毕业用，不知道能不能来得及，唉, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=19, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a2ab8713797, createdName=ms8000000394868318, createdTime=Wed Feb 21 17:21:12 CST 2024, time=2024-02-21, status=1, ipAttribution=四川省), GetPortalCommentsPageByObjectIdResponse(id=804128, encodeId=c2f9804128b3, content=审稿速度:1.0 | 投稿命中率:100.0 偏重的研究方向：神经生物学;细胞生物学;分子生物学 经验分享：赶着毕业拿学位，投稿BBRC，非常给力！7月19日晚上提交，立刻分配了稿件号并with editor，7月21日下午稿件退回要求补充上传WB的original images，当天补充完提交，提交后1小时就under review，今天7月23日中午接收，从初次提交到接收用时4天，十分效率！, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=335, replyNumber=56, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ba294682334, createdName=17142086d7m, createdTime=Thu Jul 23 15:29:56 CST 2020, time=2020-07-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2175767, encodeId=b94121e5767ad, content=审稿速度:1.0 | 投稿命中率:50.0 偏重的研究方向：动物实验;心血管;基础 经验分享：投的short communications，时间线参考： 2023.12.03 Submitted to Journal 2023.12.14 Pre-review changes required 2023.12.15 Under Review 2023.12.18 Accept 一共给BBRC投过3次稿，拒稿转投1次，接收2次。这次从Under Review到接收只花了3天，个人感觉是BBRC更注重课题的创新，逻辑思路的清晰和语言的凝练。不需要有过多的数据，但是需要有新意。按照我的经验，越快审稿说明新意越足，中的概率越大。祝大家也顺利。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=68, replyNumber=10, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTLzaUvYjJ5RKldIwAUubutpwZa2IpTuAibHjwEMk8vGIqwxTR3GEGYzO1jKlxVb3XHe6p8HNUCFt8g/132, createdBy=597d5310028, createdName=寻觅瓦尔登, createdTime=Tue Dec 19 10:51:42 CST 2023, time=2023-12-19, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=2194888, encodeId=a44f2194888de, content=请问BBRC文章查重文献和图例也查吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=7, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=13e69228095, createdName=ms9000000037149974, createdTime=Sat Mar 23 18:02:22 CST 2024, time=2024-03-23, status=1, ipAttribution=山东省), GetPortalCommentsPageByObjectIdResponse(id=2194841, encodeId=314421948414c, content=稿费多少, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=9, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9d3f9227750, createdName=ms6000001807387082, createdTime=Sat Mar 23 12:08:06 CST 2024, time=2024-03-23, status=1, ipAttribution=辽宁省), GetPortalCommentsPageByObjectIdResponse(id=2174194, encodeId=63c121e4194a6, content=11天了还是Submitted to journal,请问什么时候能进入下一节点啊, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=50, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=1b708136833, createdName=ms1000000877479508, createdTime=Mon Dec 11 09:14:15 CST 2023, time=2023-12-11, status=1, ipAttribution=海南省)]

2020-07-23 17142086d7m

审稿速度:1.0 | 投稿命中率:100.0
偏重的研究方向：神经生物学;细胞生物学;分子生物学
经验分享：赶着毕业拿学位，投稿BBRC，非常给力！7月19日晚上提交，立刻分配了稿件号并with editor，7月21日下午稿件退回要求补充上传WB的original images，当天补充完提交，提交后1小时就under review，今天7月23日中午接收，从初次提交到接收用时4天，十分效率！

335 56

展开56条回复

[GetPortalCommentsPageByObjectIdResponse(id=2198240, encodeId=46732198240d3, content=审稿速度:1.0 | 投稿命中率:5.0 偏重的研究方向：胃癌;普通外科 经验分享：3.26号投稿，2周后under review，1周后4.8日要求一些小的图片细节修改。修改了2天。4.11再次submit，8小时后reject。有点摸不清是什么意思。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c18b9149683, createdName=ms8000000859382731, createdTime=Sat Apr 13 01:12:03 CST 2024, time=2024-04-13, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=2188858, encodeId=577d21888581a, content=偏重的研究方向：鼻息肉;适应性免疫;人慢性鼻窦炎 经验分享：记录一下：投的short communication，编号：24-1285。2024.02.15 Submitted to journal，2024.02.21 Under Review。跪求诸神保佑文章可以accept！, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=17, replyNumber=6, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=90a81637022, createdName=1dd97911m23(暂无匿称), createdTime=Fri Feb 23 11:34:34 CST 2024, time=2024-02-23, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=2197697, encodeId=4bff219e6979c, content=正在投稿中, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=1, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8c615403200, createdName=ms8000000618836174, createdTime=Wed Apr 10 09:28:44 CST 2024, time=2024-04-10, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=2194249, encodeId=417e2194249d3, content=效率还可以，稳妥Accept, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=12, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/202403/72312163c68e4099952942b04fa6f369-k56lKDLhTfUF.jpg, createdBy=39cc9222865, createdName=零零一, createdTime=Wed Mar 20 11:31:37 CST 2024, time=2024-03-20, status=1, ipAttribution=广西), GetPortalCommentsPageByObjectIdResponse(id=2188536, encodeId=531a218853681, content=偏重的研究方向：中药生发 经验分享：2024.2.18晚上22.54投稿，2.19号凌晨12.59处于Submitted to Journal状态，到今天已经三天了还是Submitted to Journal状态，编号： BBRC-24-1364，期待能有个好结果吧，毕业用，不知道能不能来得及，唉, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=19, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a2ab8713797, createdName=ms8000000394868318, createdTime=Wed Feb 21 17:21:12 CST 2024, time=2024-02-21, status=1, ipAttribution=四川省), GetPortalCommentsPageByObjectIdResponse(id=804128, encodeId=c2f9804128b3, content=审稿速度:1.0 | 投稿命中率:100.0 偏重的研究方向：神经生物学;细胞生物学;分子生物学 经验分享：赶着毕业拿学位，投稿BBRC，非常给力！7月19日晚上提交，立刻分配了稿件号并with editor，7月21日下午稿件退回要求补充上传WB的original images，当天补充完提交，提交后1小时就under review，今天7月23日中午接收，从初次提交到接收用时4天，十分效率！, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=335, replyNumber=56, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ba294682334, createdName=17142086d7m, createdTime=Thu Jul 23 15:29:56 CST 2020, time=2020-07-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2175767, encodeId=b94121e5767ad, content=审稿速度:1.0 | 投稿命中率:50.0 偏重的研究方向：动物实验;心血管;基础 经验分享：投的short communications，时间线参考： 2023.12.03 Submitted to Journal 2023.12.14 Pre-review changes required 2023.12.15 Under Review 2023.12.18 Accept 一共给BBRC投过3次稿，拒稿转投1次，接收2次。这次从Under Review到接收只花了3天，个人感觉是BBRC更注重课题的创新，逻辑思路的清晰和语言的凝练。不需要有过多的数据，但是需要有新意。按照我的经验，越快审稿说明新意越足，中的概率越大。祝大家也顺利。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=68, replyNumber=10, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTLzaUvYjJ5RKldIwAUubutpwZa2IpTuAibHjwEMk8vGIqwxTR3GEGYzO1jKlxVb3XHe6p8HNUCFt8g/132, createdBy=597d5310028, createdName=寻觅瓦尔登, createdTime=Tue Dec 19 10:51:42 CST 2023, time=2023-12-19, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=2194888, encodeId=a44f2194888de, content=请问BBRC文章查重文献和图例也查吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=7, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=13e69228095, createdName=ms9000000037149974, createdTime=Sat Mar 23 18:02:22 CST 2024, time=2024-03-23, status=1, ipAttribution=山东省), GetPortalCommentsPageByObjectIdResponse(id=2194841, encodeId=314421948414c, content=稿费多少, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=9, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9d3f9227750, createdName=ms6000001807387082, createdTime=Sat Mar 23 12:08:06 CST 2024, time=2024-03-23, status=1, ipAttribution=辽宁省), GetPortalCommentsPageByObjectIdResponse(id=2174194, encodeId=63c121e4194a6, content=11天了还是Submitted to journal,请问什么时候能进入下一节点啊, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=50, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=1b708136833, createdName=ms1000000877479508, createdTime=Mon Dec 11 09:14:15 CST 2023, time=2023-12-11, status=1, ipAttribution=海南省)]

2023-12-19 寻觅瓦尔登来自上海

审稿速度:1.0 | 投稿命中率:50.0
偏重的研究方向：动物实验;心血管;基础
经验分享：投的short communications，时间线参考：
2023.12.03 Submitted to Journal
2023.12.14 Pre-review changes required
2023.12.15 Under Review
2023.12.18 Accept
一共给BBRC投过3次稿，拒稿转投1次，接收2次。这次从Under Review到接收只花了3天，个人感觉是BBRC更注重课题的创新，逻辑思路的清晰和语言的凝练。不需要有过多的数据，但是需要有新意。按照我的经验，越快审稿说明新意越足，中的概率越大。祝大家也顺利。

68 10

展开10条回复

[GetPortalCommentsPageByObjectIdResponse(id=2198240, encodeId=46732198240d3, content=审稿速度:1.0 | 投稿命中率:5.0 偏重的研究方向：胃癌;普通外科 经验分享：3.26号投稿，2周后under review，1周后4.8日要求一些小的图片细节修改。修改了2天。4.11再次submit，8小时后reject。有点摸不清是什么意思。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c18b9149683, createdName=ms8000000859382731, createdTime=Sat Apr 13 01:12:03 CST 2024, time=2024-04-13, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=2188858, encodeId=577d21888581a, content=偏重的研究方向：鼻息肉;适应性免疫;人慢性鼻窦炎 经验分享：记录一下：投的short communication，编号：24-1285。2024.02.15 Submitted to journal，2024.02.21 Under Review。跪求诸神保佑文章可以accept！, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=17, replyNumber=6, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=90a81637022, createdName=1dd97911m23(暂无匿称), createdTime=Fri Feb 23 11:34:34 CST 2024, time=2024-02-23, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=2197697, encodeId=4bff219e6979c, content=正在投稿中, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=1, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8c615403200, createdName=ms8000000618836174, createdTime=Wed Apr 10 09:28:44 CST 2024, time=2024-04-10, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=2194249, encodeId=417e2194249d3, content=效率还可以，稳妥Accept, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=12, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/202403/72312163c68e4099952942b04fa6f369-k56lKDLhTfUF.jpg, createdBy=39cc9222865, createdName=零零一, createdTime=Wed Mar 20 11:31:37 CST 2024, time=2024-03-20, status=1, ipAttribution=广西), GetPortalCommentsPageByObjectIdResponse(id=2188536, encodeId=531a218853681, content=偏重的研究方向：中药生发 经验分享：2024.2.18晚上22.54投稿，2.19号凌晨12.59处于Submitted to Journal状态，到今天已经三天了还是Submitted to Journal状态，编号： BBRC-24-1364，期待能有个好结果吧，毕业用，不知道能不能来得及，唉, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=19, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a2ab8713797, createdName=ms8000000394868318, createdTime=Wed Feb 21 17:21:12 CST 2024, time=2024-02-21, status=1, ipAttribution=四川省), GetPortalCommentsPageByObjectIdResponse(id=804128, encodeId=c2f9804128b3, content=审稿速度:1.0 | 投稿命中率:100.0 偏重的研究方向：神经生物学;细胞生物学;分子生物学 经验分享：赶着毕业拿学位，投稿BBRC，非常给力！7月19日晚上提交，立刻分配了稿件号并with editor，7月21日下午稿件退回要求补充上传WB的original images，当天补充完提交，提交后1小时就under review，今天7月23日中午接收，从初次提交到接收用时4天，十分效率！, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=335, replyNumber=56, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ba294682334, createdName=17142086d7m, createdTime=Thu Jul 23 15:29:56 CST 2020, time=2020-07-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2175767, encodeId=b94121e5767ad, content=审稿速度:1.0 | 投稿命中率:50.0 偏重的研究方向：动物实验;心血管;基础 经验分享：投的short communications，时间线参考： 2023.12.03 Submitted to Journal 2023.12.14 Pre-review changes required 2023.12.15 Under Review 2023.12.18 Accept 一共给BBRC投过3次稿，拒稿转投1次，接收2次。这次从Under Review到接收只花了3天，个人感觉是BBRC更注重课题的创新，逻辑思路的清晰和语言的凝练。不需要有过多的数据，但是需要有新意。按照我的经验，越快审稿说明新意越足，中的概率越大。祝大家也顺利。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=68, replyNumber=10, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTLzaUvYjJ5RKldIwAUubutpwZa2IpTuAibHjwEMk8vGIqwxTR3GEGYzO1jKlxVb3XHe6p8HNUCFt8g/132, createdBy=597d5310028, createdName=寻觅瓦尔登, createdTime=Tue Dec 19 10:51:42 CST 2023, time=2023-12-19, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=2194888, encodeId=a44f2194888de, content=请问BBRC文章查重文献和图例也查吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=7, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=13e69228095, createdName=ms9000000037149974, createdTime=Sat Mar 23 18:02:22 CST 2024, time=2024-03-23, status=1, ipAttribution=山东省), GetPortalCommentsPageByObjectIdResponse(id=2194841, encodeId=314421948414c, content=稿费多少, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=9, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9d3f9227750, createdName=ms6000001807387082, createdTime=Sat Mar 23 12:08:06 CST 2024, time=2024-03-23, status=1, ipAttribution=辽宁省), GetPortalCommentsPageByObjectIdResponse(id=2174194, encodeId=63c121e4194a6, content=11天了还是Submitted to journal,请问什么时候能进入下一节点啊, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=50, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=1b708136833, createdName=ms1000000877479508, createdTime=Mon Dec 11 09:14:15 CST 2023, time=2023-12-11, status=1, ipAttribution=海南省)]

2024-03-23 ms9000000037149974 来自山东省

请问BBRC文章查重文献和图例也查吗

7 0

[GetPortalCommentsPageByObjectIdResponse(id=2198240, encodeId=46732198240d3, content=审稿速度:1.0 | 投稿命中率:5.0 偏重的研究方向：胃癌;普通外科 经验分享：3.26号投稿，2周后under review，1周后4.8日要求一些小的图片细节修改。修改了2天。4.11再次submit，8小时后reject。有点摸不清是什么意思。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c18b9149683, createdName=ms8000000859382731, createdTime=Sat Apr 13 01:12:03 CST 2024, time=2024-04-13, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=2188858, encodeId=577d21888581a, content=偏重的研究方向：鼻息肉;适应性免疫;人慢性鼻窦炎 经验分享：记录一下：投的short communication，编号：24-1285。2024.02.15 Submitted to journal，2024.02.21 Under Review。跪求诸神保佑文章可以accept！, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=17, replyNumber=6, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=90a81637022, createdName=1dd97911m23(暂无匿称), createdTime=Fri Feb 23 11:34:34 CST 2024, time=2024-02-23, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=2197697, encodeId=4bff219e6979c, content=正在投稿中, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=1, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8c615403200, createdName=ms8000000618836174, createdTime=Wed Apr 10 09:28:44 CST 2024, time=2024-04-10, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=2194249, encodeId=417e2194249d3, content=效率还可以，稳妥Accept, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=12, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/202403/72312163c68e4099952942b04fa6f369-k56lKDLhTfUF.jpg, createdBy=39cc9222865, createdName=零零一, createdTime=Wed Mar 20 11:31:37 CST 2024, time=2024-03-20, status=1, ipAttribution=广西), GetPortalCommentsPageByObjectIdResponse(id=2188536, encodeId=531a218853681, content=偏重的研究方向：中药生发 经验分享：2024.2.18晚上22.54投稿，2.19号凌晨12.59处于Submitted to Journal状态，到今天已经三天了还是Submitted to Journal状态，编号： BBRC-24-1364，期待能有个好结果吧，毕业用，不知道能不能来得及，唉, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=19, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a2ab8713797, createdName=ms8000000394868318, createdTime=Wed Feb 21 17:21:12 CST 2024, time=2024-02-21, status=1, ipAttribution=四川省), GetPortalCommentsPageByObjectIdResponse(id=804128, encodeId=c2f9804128b3, content=审稿速度:1.0 | 投稿命中率:100.0 偏重的研究方向：神经生物学;细胞生物学;分子生物学 经验分享：赶着毕业拿学位，投稿BBRC，非常给力！7月19日晚上提交，立刻分配了稿件号并with editor，7月21日下午稿件退回要求补充上传WB的original images，当天补充完提交，提交后1小时就under review，今天7月23日中午接收，从初次提交到接收用时4天，十分效率！, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=335, replyNumber=56, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ba294682334, createdName=17142086d7m, createdTime=Thu Jul 23 15:29:56 CST 2020, time=2020-07-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2175767, encodeId=b94121e5767ad, content=审稿速度:1.0 | 投稿命中率:50.0 偏重的研究方向：动物实验;心血管;基础 经验分享：投的short communications，时间线参考： 2023.12.03 Submitted to Journal 2023.12.14 Pre-review changes required 2023.12.15 Under Review 2023.12.18 Accept 一共给BBRC投过3次稿，拒稿转投1次，接收2次。这次从Under Review到接收只花了3天，个人感觉是BBRC更注重课题的创新，逻辑思路的清晰和语言的凝练。不需要有过多的数据，但是需要有新意。按照我的经验，越快审稿说明新意越足，中的概率越大。祝大家也顺利。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=68, replyNumber=10, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTLzaUvYjJ5RKldIwAUubutpwZa2IpTuAibHjwEMk8vGIqwxTR3GEGYzO1jKlxVb3XHe6p8HNUCFt8g/132, createdBy=597d5310028, createdName=寻觅瓦尔登, createdTime=Tue Dec 19 10:51:42 CST 2023, time=2023-12-19, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=2194888, encodeId=a44f2194888de, content=请问BBRC文章查重文献和图例也查吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=7, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=13e69228095, createdName=ms9000000037149974, createdTime=Sat Mar 23 18:02:22 CST 2024, time=2024-03-23, status=1, ipAttribution=山东省), GetPortalCommentsPageByObjectIdResponse(id=2194841, encodeId=314421948414c, content=稿费多少, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=9, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9d3f9227750, createdName=ms6000001807387082, createdTime=Sat Mar 23 12:08:06 CST 2024, time=2024-03-23, status=1, ipAttribution=辽宁省), GetPortalCommentsPageByObjectIdResponse(id=2174194, encodeId=63c121e4194a6, content=11天了还是Submitted to journal,请问什么时候能进入下一节点啊, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=50, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=1b708136833, createdName=ms1000000877479508, createdTime=Mon Dec 11 09:14:15 CST 2023, time=2023-12-11, status=1, ipAttribution=海南省)]

2024-03-23 ms6000001807387082 来自辽宁省

稿费多少

9 1

展开1条回复

[GetPortalCommentsPageByObjectIdResponse(id=2198240, encodeId=46732198240d3, content=审稿速度:1.0 | 投稿命中率:5.0 偏重的研究方向：胃癌;普通外科 经验分享：3.26号投稿，2周后under review，1周后4.8日要求一些小的图片细节修改。修改了2天。4.11再次submit，8小时后reject。有点摸不清是什么意思。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c18b9149683, createdName=ms8000000859382731, createdTime=Sat Apr 13 01:12:03 CST 2024, time=2024-04-13, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=2188858, encodeId=577d21888581a, content=偏重的研究方向：鼻息肉;适应性免疫;人慢性鼻窦炎 经验分享：记录一下：投的short communication，编号：24-1285。2024.02.15 Submitted to journal，2024.02.21 Under Review。跪求诸神保佑文章可以accept！, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=17, replyNumber=6, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=90a81637022, createdName=1dd97911m23(暂无匿称), createdTime=Fri Feb 23 11:34:34 CST 2024, time=2024-02-23, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=2197697, encodeId=4bff219e6979c, content=正在投稿中, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=1, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8c615403200, createdName=ms8000000618836174, createdTime=Wed Apr 10 09:28:44 CST 2024, time=2024-04-10, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=2194249, encodeId=417e2194249d3, content=效率还可以，稳妥Accept, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=12, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/202403/72312163c68e4099952942b04fa6f369-k56lKDLhTfUF.jpg, createdBy=39cc9222865, createdName=零零一, createdTime=Wed Mar 20 11:31:37 CST 2024, time=2024-03-20, status=1, ipAttribution=广西), GetPortalCommentsPageByObjectIdResponse(id=2188536, encodeId=531a218853681, content=偏重的研究方向：中药生发 经验分享：2024.2.18晚上22.54投稿，2.19号凌晨12.59处于Submitted to Journal状态，到今天已经三天了还是Submitted to Journal状态，编号： BBRC-24-1364，期待能有个好结果吧，毕业用，不知道能不能来得及，唉, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=19, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a2ab8713797, createdName=ms8000000394868318, createdTime=Wed Feb 21 17:21:12 CST 2024, time=2024-02-21, status=1, ipAttribution=四川省), GetPortalCommentsPageByObjectIdResponse(id=804128, encodeId=c2f9804128b3, content=审稿速度:1.0 | 投稿命中率:100.0 偏重的研究方向：神经生物学;细胞生物学;分子生物学 经验分享：赶着毕业拿学位，投稿BBRC，非常给力！7月19日晚上提交，立刻分配了稿件号并with editor，7月21日下午稿件退回要求补充上传WB的original images，当天补充完提交，提交后1小时就under review，今天7月23日中午接收，从初次提交到接收用时4天，十分效率！, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=335, replyNumber=56, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ba294682334, createdName=17142086d7m, createdTime=Thu Jul 23 15:29:56 CST 2020, time=2020-07-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2175767, encodeId=b94121e5767ad, content=审稿速度:1.0 | 投稿命中率:50.0 偏重的研究方向：动物实验;心血管;基础 经验分享：投的short communications，时间线参考： 2023.12.03 Submitted to Journal 2023.12.14 Pre-review changes required 2023.12.15 Under Review 2023.12.18 Accept 一共给BBRC投过3次稿，拒稿转投1次，接收2次。这次从Under Review到接收只花了3天，个人感觉是BBRC更注重课题的创新，逻辑思路的清晰和语言的凝练。不需要有过多的数据，但是需要有新意。按照我的经验，越快审稿说明新意越足，中的概率越大。祝大家也顺利。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=68, replyNumber=10, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTLzaUvYjJ5RKldIwAUubutpwZa2IpTuAibHjwEMk8vGIqwxTR3GEGYzO1jKlxVb3XHe6p8HNUCFt8g/132, createdBy=597d5310028, createdName=寻觅瓦尔登, createdTime=Tue Dec 19 10:51:42 CST 2023, time=2023-12-19, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=2194888, encodeId=a44f2194888de, content=请问BBRC文章查重文献和图例也查吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=7, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=13e69228095, createdName=ms9000000037149974, createdTime=Sat Mar 23 18:02:22 CST 2024, time=2024-03-23, status=1, ipAttribution=山东省), GetPortalCommentsPageByObjectIdResponse(id=2194841, encodeId=314421948414c, content=稿费多少, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=9, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9d3f9227750, createdName=ms6000001807387082, createdTime=Sat Mar 23 12:08:06 CST 2024, time=2024-03-23, status=1, ipAttribution=辽宁省), GetPortalCommentsPageByObjectIdResponse(id=2174194, encodeId=63c121e4194a6, content=11天了还是Submitted to journal,请问什么时候能进入下一节点啊, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=50, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=1b708136833, createdName=ms1000000877479508, createdTime=Mon Dec 11 09:14:15 CST 2023, time=2023-12-11, status=1, ipAttribution=海南省)]

2023-12-11 ms1000000877479508 来自海南省

11天了还是Submitted to journal,请问什么时候能进入下一节点啊

50 3

展开3条回复

内科

外科

专科科室

热点

按科室浏览

临床工具

科研工具

其他工具

科研数智化

真实世界研究解决方案

数字化学术传播解决方案

其它

期刊讨论

科室

工具

服务